1.Introduction: Why the Pharmaceutical Sector Matters
The pharmaceutical sector is one of the most essential yet complex sectors for investors. Unlike many cyclical businesses, demand for medicines does not disappear during recessions, political instability, or inflationary periods. People continue to need painkillers, antibiotics, diabetes medicines, blood-pressure drugs, vaccines, vitamins, supplements, and hospital medicines regardless of the economic cycle. This gives the sector a defensive character.
However, pharmaceutical companies are not simple consumer-goods companies. Their profitability depends on a mixture of regulation, product portfolio, pricing policy, raw-material sourcing, foreign exchange, doctor prescriptions, brand strength, manufacturing quality, distribution networks, and compliance with health authorities. In Pakistan, the sector is even more complicated because drug prices have historically been controlled by the government, while most raw materials are imported in foreign currency. This creates a constant tension: costs move with the dollar, global APIs, freight, energy and inflation, but prices may not always move freely.
For an investor, the key question is not only whether a company sells medicines. The real question is: what type of medicines does it sell, how are those medicines priced, how much pricing power does the company have, how much of the input cost is imported, how strong are its brands, how diversified is its product portfolio, and whether earnings growth is sustainable or merely the result of one-time price increases.
The Pakistan pharmaceutical sector has recently become more attractive because of the deregulation of non-essential drug prices, improved gross margins, lower finance costs, and lower API cost trends. But investors must remain careful. The sector is still exposed to regulatory intervention, currency depreciation, imported raw materials, quality standards, export barriers, and political sensitivity around medicine prices.

 

2.Basic Structure of the Pharmaceutical Business
A pharmaceutical company is essentially involved in converting active ingredients and other materials into finished medicines that can be sold to patients, hospitals, pharmacies, distributors and institutions.
A medicine usually has two broad types of ingredients. The first is the Active Pharmaceutical Ingredient, or API. This is the actual chemical or biological substance that produces the therapeutic effect. For example, paracetamol is the API in Panadol-type fever and pain medicines. Metformin is the API in many diabetes medicines. Amlodipine is the API in many blood-pressure medicines.
The second category is excipients. These are inactive ingredients that help convert the API into a usable product. Excipients include fillers, binders, disintegrants, coating agents, stabilizers, preservatives, sweeteners, flavors and solvents. In tablets, excipients help the tablet maintain shape, dissolve at the right speed, and remain stable during storage. In syrups, excipients help with taste, suspension, preservation and stability. In creams and gels, excipients affect texture and absorption.
After APIs and excipients are procured, the company manufactures the final dosage form. These dosage forms may include tablets, capsules, syrups, injections, creams, gels, sachets, effervescent tablets, inhalers, drops and ointments. The finished product is then packed in blister packs, bottles, tubes, cartons, sachets or strips and distributed through wholesalers, distributors, pharmacies, hospitals or institutional channels.
In Pakistan, most pharmaceutical companies are not basic research companies. They usually do not discover new molecules. The sector is largely based on branded generics, consumer healthcare products, OTC medicines, nutraceuticals, and imported or locally manufactured formulations. This means that the business model is closer to manufacturing, branding, distribution and regulatory execution rather than original global drug discovery.


3.Drug Discovery vs Generic Pharmaceutical Manufacturing
Globally, pharmaceutical companies can be divided into several types.
The first category is innovator pharmaceutical companies. These are global companies that spend billions of dollars on research and development to discover new molecules. They conduct pre-clinical research, clinical trials, regulatory submissions, patent filings, and global commercialization. Examples include large multinational companies that develop new cancer drugs, diabetes drugs, vaccines, biologics and specialty therapies.
The second category is generic pharmaceutical companies. These companies manufacture versions of drugs whose patents have expired. Generic companies compete on manufacturing quality, cost, regulatory approvals, scale, distribution and brand positioning. In Pakistan, most local pharmaceutical companies fall into this broad category, although many sell branded generics rather than purely unbranded generics.

The third category is branded-generic companies. This is very important in Pakistan. A branded generic is a generic medicine sold under a brand name. For example, two companies may sell the same molecule, but doctors and patients may prefer one brand because of trust, marketing, distribution, quality perception and doctor loyalty. Pakistan is heavily driven by branded generics because doctors often prescribe brands rather than only molecule names.
The fourth category is consumer healthcare and OTC companies. These sell products that can be purchased without prescription, such as pain relief, vitamins, supplements, digestive products, oral care, cold and flu products, and wellness products. Companies like Haleon Pakistan are important in this area because products such as Panadol, CAC-1000, Centrum and Sensodyne have strong consumer recall.
The fifth category is biotech and biosimilar companies. These deal with biological products, vaccines, insulin, hormones, monoclonal antibodies and biosimilars. This is a more complex area because manufacturing requires higher technical capability, stricter quality systems and more difficult regulatory approvals. In Pakistan, this segment is still developing but can become important over time.
4.Key Pharmaceutical Product Segments in Pakistan
Pakistan’s pharmaceutical market can be divided in several ways.
a.Essential Medicines
Essential medicines are products listed on the National Essential Medicines List. These include medicines considered necessary for public health. Examples include medicines used in fever, pain, infections, diabetes, cardiovascular diseases, respiratory diseases, psychiatric conditions and other common therapeutic needs.
Essential drugs remain more regulated. Their pricing is usually controlled under DRAP’s framework. For investors, essential medicines provide steady demand but limited pricing flexibility. If input costs rise quickly and prices cannot be adjusted in time, margins can come under pressure.
b.Non-Essential Medicines
Non-essential medicines are medicines not included in the National Essential Medicines List. The major change in 2024 was the deregulation of non-essential drug prices. This gave pharmaceutical companies greater pricing freedom for such products. Companies with a higher share of non-essential drugs received a major profitability advantage because they could adjust prices more freely in response to inflation, rupee depreciation and API cost changes.
For investors, the percentage of revenue coming from non-essential medicines has become one of the most important indicators of pricing power.

c.Prescription Medicines
Prescription medicines are medicines that require a doctor’s prescription. Companies cannot generally advertise these directly to patients through mass media. Their sales depend on doctor prescriptions, medical representatives, product quality, brand trust, availability, and relationships with healthcare professionals.
Prescription portfolios include antibiotics, cardiovascular drugs, diabetes drugs, respiratory medicines, pain medicines, psychiatric medicines, dermatology products, gastroenterology products and many chronic-disease therapies.
d.OTC and Consumer Healthcare Products
Over-the-counter products can be bought directly by consumers from pharmacies without a prescription. These include products such as pain relief, vitamins, supplements, oral care, digestive products, cold and flu relief, and general wellness products.
OTC products are attractive because companies can advertise them, build consumer brands, and often enjoy better pricing flexibility. Strong OTC brands can behave more like FMCG products than regulated prescription drugs. Haleon’s portfolio is a useful example because products like Panadol, CAC-1000, Centrum and Sensodyne have strong consumer recognition.
e.Nutraceuticals and Supplements
Nutraceuticals include vitamins, minerals, calcium products, immunity products, digestive health products, women’s health supplements, bone health products and other preventive-health products. This segment is attractive because consumers are becoming more health-conscious and because many products may have better pricing flexibility than strictly regulated medicines.
However, this category can also face competition from imported supplements, grey-market products, local low-cost brands, and changing consumer preferences.
f.Chronic vs Acute Therapies
This is one of the most important investor distinctions.
Acute therapies treat short-term conditions, such as fever, infection, pain, cough or flu. These products may have seasonal demand and can be affected by disease outbreaks, weather patterns and prescription trends.
Chronic therapies treat long-term conditions such as diabetes, hypertension, heart disease, asthma, psychiatric disorders and cholesterol. Chronic medicines are attractive because patients take them regularly for years. This creates recurring revenue and better earnings visibility.
Companies with strong chronic portfolios often deserve better valuation multiples because their sales are less volatile and more predictable.

5.Pharmaceutical Production Process
The production of medicines involves several steps.
First, the company sources APIs and excipients. In Pakistan, most APIs are imported, mainly from China, India and other international suppliers. This makes procurement extremely important. A company that can source quality APIs at competitive prices has a major advantage.
Second, the company conducts quality testing of raw materials. APIs must meet required specifications for purity, potency, safety and stability. Poor-quality API can lead to ineffective medicines, regulatory issues, recalls and reputational damage.
Third, the company manufactures the dosage form. For tablets, the process may include weighing, mixing, granulation, drying, compression, coating and packaging. For capsules, it may include blending and capsule filling. For syrups, it may involve mixing, dissolving, filtration, filling and sealing. For injections, the process is more sensitive because sterility is critical. Injectable manufacturing requires stricter controls, sterile areas, clean rooms and validation.
Fourth, the company performs quality-control testing on finished products. It checks whether the medicine contains the right amount of API, dissolves correctly, is stable, is free from contamination, and meets regulatory standards.
Fifth, the medicine is packed and distributed. Packaging is not a minor cost. Blister foil, PVC/PVDC film, bottles, cartons, labels, sachets and tubes can significantly affect cost, especially for high-volume, low-price products.
Sixth, the company sells through distributors, pharmacies, hospitals and institutions. In Pakistan, many pharmaceutical companies sell to distributors on an advance-payment basis. This means receivables are often low and cash conversion can be strong. A low days-sales-outstanding profile is a major positive for working capital.


6.Regulation and Pricing Policy in Pakistan
Regulation is the heart of pharmaceutical investing in Pakistan. The Drug Regulatory Authority of Pakistan, or DRAP, regulates registration, pricing, licensing, quality, manufacturing standards, imports, advertising and other aspects of the sector.
Historically, pharmaceutical companies complained that prices were too tightly controlled while input costs were rising rapidly. Since APIs, excipients, packaging and machinery are often imported, rupee depreciation can increase costs significantly. If the company cannot pass on those cost increases through higher prices, gross margins fall.
The Drug Pricing Policy 2018 created a framework under which essential and non-essential medicine prices could be increased based on CPI-linked formulas. Essential medicines had lower allowed increases, while non-essential medicines had somewhat higher flexibility. However,

even that framework did not always fully protect companies during periods of extreme rupee depreciation and inflation.
The major turning point came in February 2024, when the government approved deregulation of non-essential drug prices. This meant companies gained much greater freedom to price non-essential medicines. Essential medicines remained regulated. This policy change was a major trigger for earnings recovery in the sector.
For an investor, the crucial issue is to evaluate how much of a company’s revenue comes from essential drugs versus non-essential drugs. A company with a higher non-essential, OTC, consumer-health or nutraceutical portfolio has more pricing flexibility. A company heavily dependent on essential regulated medicines may have stronger demand stability but weaker margin protection.


7.Why Deregulation Changed the Sector’s Profitability
The deregulation of non-essential drug prices changed the economics of the sector because it improved the ability of companies to pass on cost increases.
Before deregulation, many companies were trapped between rising imported costs and controlled selling prices. If the rupee depreciated or API prices rose, companies could not always raise prices quickly enough. As a result, gross margins declined and earnings became volatile.
After deregulation, companies with non-essential portfolios could raise prices more freely. This allowed revenue growth to become price-led. At the same time, global API prices softened in several categories and interest rates declined, reducing finance costs. These three forces created a powerful earnings recovery:
1.Higher selling prices

2.Lower or stable API costs

3.Lower finance costs
This is why listed pharmaceutical companies reported record profits in 2025. But investors must understand the quality of this growth. If earnings improved mainly because of one-time price increases, the market may not immediately assign a very high P/E multiple. For a sustainable re-rating, companies must show volume growth, new product launches, export growth, better product mix and stable policy support.


8.Raw Material and API Dependence
Pakistan’s pharmaceutical sector is highly dependent on imported APIs and raw materials. This is one of the biggest structural weaknesses of the sector.

APIs are the most important direct cost input. Many APIs are sourced from China, India and other international suppliers. Excipients, packaging materials, specialty chemicals, flavors, coatings and machinery may also be imported. This creates three risks.
First, there is foreign-exchange risk. If the rupee depreciates, imported raw materials become more expensive even if international prices are unchanged.
Second, there is global supply-chain risk. If Chinese or Indian API factories face shutdowns, environmental restrictions, energy shortages, export restrictions, shipping disruptions or geopolitical tensions, API prices can rise sharply.
Third, there is quality risk. Pharmaceutical companies cannot simply buy the cheapest API. The supplier must meet quality standards. If quality is compromised, the finished medicine may fail regulatory or stability tests.
The procurement function is therefore central to pharma profitability. A strong procurement team can protect margins by finding reliable, cost-effective suppliers, negotiating better terms, holding inventory at the right time, and avoiding supply shortages.


9.Link Between Oil, Petrochemicals and API Prices
Many APIs and excipients are indirectly linked to crude oil and petrochemicals. This is because APIs often use chemical intermediates such as benzene, toluene, xylene, phenol, acetone, ethylene, propylene, methanol and other petroleum-derived chemicals.
For example, paracetamol is linked to phenol and p-aminophenol chains. Ibuprofen is linked to petrochemical intermediates such as benzene, isobutylbenzene and propylene. Aspirin is linked to phenol-derived salicylic acid and acetic anhydride. Many PPIs, painkillers, antihistamines, cardiac drugs and antibiotics use petrochemical-linked solvents or intermediates.
Even if the API itself is not directly derived from crude oil, API manufacturing uses solvents, energy, freight, packaging and imported intermediates. Therefore, higher oil prices can increase API costs through multiple channels: raw materials, solvents, energy, freight, packaging, working capital and currency pressure.
For investors, tracking oil prices alone is not enough. One should also monitor specific API prices, China/India chemical markets, freight rates, PKR/USD, and packaging costs such as aluminum foil and PVC/PVDC blister film.


10.Packaging as a Major Cost Driver
Many investors underestimate packaging cost in pharmaceutical companies. Packaging is critical because medicines must remain stable, safe, protected and compliant with labeling requirements.
Pharmaceutical packaging includes aluminum foil, PVC/PVDC blister films, bottles, caps, tubes, labels, cartons, sachets, leaflets, printed material and shipping cartons. For high-volume

products like paracetamol tablets, packaging can be a major cost item because every strip requires foil and film.
Packaging costs are linked to aluminum prices, plastic resin prices, paper prices, printing costs, energy costs and freight. In low-priced regulated medicines, a rise in packaging cost can materially reduce margins if selling prices cannot be adjusted.
Companies with strong pricing power, premium products or deregulated portfolios can pass on packaging inflation more easily. Companies selling regulated essential medicines may face more margin pressure.


11.Product Mix: The Most Important Profitability Driver
A pharmaceutical company’s profitability depends heavily on its product mix.
A company with high exposure to regulated essential medicines may have steady demand but limited pricing power. A company with high exposure to non-essential medicines, OTC products, nutraceuticals or premium branded generics may have better pricing flexibility and higher margins.
A company with chronic therapies may enjoy recurring demand. A company with seasonal acute therapies may see volatile quarterly sales. A company with a few blockbuster brands may enjoy strong margins but also face concentration risk. A company with a diversified portfolio may have more stability but slower growth.
For example, an investor should not treat Panadol, antibiotics, diabetes medicine, calcium supplements, toothpaste, injectable biologics and dermatology creams as the same type of product. Each has different pricing rules, demand drivers, margins, marketing restrictions and risk profile.
A good pharmaceutical investor should always ask:
What are the company’s top 5 brands?
What percentage of sales comes from top brands?
Are the top products essential or non-essential?
Are they prescription or OTC?
Are they acute or chronic?
Are they locally manufactured or imported?
Are APIs imported or locally sourced?
Is there export potential?
Are margins improving because of price increases, volume growth or lower input costs?


12.Brand Equity and Doctor Loyalty
In Pakistan, brand strength is extremely important. Since the market is branded-generic oriented, doctors often prescribe trusted brands. Patients also prefer known names, especially

for common products such as painkillers, vitamins, antibiotics, diabetes medicines and heart medicines.
Strong brands create pricing power, repeat prescriptions, better shelf space, and distributor confidence. A well-known brand can defend market share even if cheaper alternatives exist. This is why companies with established brands often trade at higher valuation multiples.
However, brand equity must be maintained through product quality, availability, medical marketing, doctor engagement, and consumer trust. Any quality failure, shortage or regulatory issue can damage a brand.
For OTC products, advertising is very important. A company can directly advertise consumer-health products and create household recognition. For prescription products, direct-to-consumer advertising is restricted, so companies rely more on medical representatives, doctor engagement, conferences, samples, product literature and institutional relationships.
 

13.Distribution and Working Capital
The distribution model is a major strength of many Pakistani pharmaceutical companies. Several companies sell products to distributors on advance payment or very short credit terms. This means receivables are low and cash conversion is strong.
Low days-sales-outstanding is valuable because it reduces working-capital risk. In many manufacturing sectors, companies suffer because sales are booked but cash is received after months. In pharma, if distributors pay in advance or quickly, the business can generate cash more efficiently.
However, inventory management is still critical. Companies must hold APIs, packaging material and finished goods. If they overstock APIs and prices fall, margins may suffer. If they understock and supply is disrupted, sales may be lost. Imported raw materials also require letters of credit, foreign currency planning and regulatory clearance.
A good investor should track inventory days, trade debts, cash conversion cycle, short-term borrowings and finance costs.


14.Manufacturing Quality and Regulatory Compliance
Pharmaceutical manufacturing is not like ordinary manufacturing. Quality compliance is essential. A small error in dosage, contamination, stability, labeling or storage can create health risks and regulatory penalties.
Companies must comply with Good Manufacturing Practices, quality-control systems, validation requirements, stability testing, batch documentation and regulatory inspections. Higher-quality facilities can support exports and premium products. Poor-quality facilities restrict growth and expose the company to recalls or regulatory action.
For exports, quality standards become even more important. To enter regulated markets, companies may need international certifications, bioequivalence studies, stability data, product

dossiers and compliance with foreign regulatory agencies. This is why Pakistan’s pharma exports remain limited compared with India and Bangladesh.
Investors should prefer companies that invest consistently in plant modernization, quality systems, compliance, laboratories and certifications.


15.Exports: Opportunity and Challenge
Pakistan’s pharma export potential is significant but underdeveloped. The country has a large domestic manufacturing base, many experienced companies, and lower production costs compared with some developed markets. But exports remain limited because of regulatory barriers, weak international marketing, limited API base, lack of scale, and difficulty entering stringent regulatory markets.
Export growth can be a major re-rating trigger for the sector. If a company can export to Africa, Central Asia, Southeast Asia, the Middle East or regulated markets, it reduces dependence on domestic pricing policy. Exports also provide dollar revenue, which can naturally hedge imported raw-material costs.
However, exports are not easy. Companies must meet importing-country regulatory requirements, maintain quality consistency, manage documentation, handle registrations, compete with Indian and Chinese suppliers, and build distribution networks abroad.
Investors should track:
Export sales as a percentage of revenue
Number of countries served
Product registrations in export markets
Export margins
Currency of export revenue
Whether exports are branded, contract manufacturing, institutional tenders or generic supply


16.Company-Level Profitability Drivers
A pharmaceutical company’s profitability depends on several interlinked variables.
a.Sales Growth
Sales growth can come from higher prices, higher volumes, new launches, acquisitions, exports, or better distribution. Investors must separate price-led growth from volume-led growth. Price-led growth can improve earnings quickly, but volume-led growth is usually more sustainable.

b.Gross Margin
Gross margin is the most important profitability metric. It reflects selling price minus cost of goods sold. A company with strong brands, non-essential products, efficient procurement and better product mix can enjoy higher gross margins.
c.API and Raw-Material Costs
If API prices fall, gross margins improve. If API prices rise and the company cannot pass on the cost, margins shrink. This is especially important for essential regulated drugs.
d.Product Mix
A shift from low-margin commodity generics to high-margin branded products, OTC products, chronic therapies or nutraceuticals can improve margins.
e.Finance Cost
Pharma companies with low debt benefit from lower financial risk. Companies with high short-term borrowings are sensitive to interest rates. Falling interest rates can improve net profit even if operating profit remains stable.
f.Tax Rate
Pharma companies may face high effective tax rates. Investors should not only look at profit before tax. Net profit after tax is what belongs to shareholders.
g.Operating Expenses
Selling, marketing and distribution expenses are important because pharma companies rely on field forces, doctor engagement, promotional material and distribution networks. A company with high marketing spend may be investing for growth, but if expenses rise faster than sales, operating leverage weakens.
h.Capacity Utilization
If a company has underutilized plants, higher volume can improve margins by spreading fixed costs. If plants are running near capacity, future growth may require capex.
i.New Product Launches
New launches can drive growth, especially if they enter high-margin therapeutic areas. But launches require regulatory approvals, marketing investment and doctor acceptance.
 

17.How to Read a Pharmaceutical Company’s Financial Statements
An investor should analyze a pharma company differently from a cement, textile or bank.

Start with revenue growth. Break it down into price, volume and new products. If revenue is rising only because of price increases, check whether volumes are stable. If volumes are falling, growth quality may be weak.
Then analyze gross margin. Compare current gross margin with the last five years. If margins have improved sharply, identify whether the reason is deregulation, lower API cost, better product mix, price increases or accounting effects.
Next, look at selling and distribution expenses. Pharma companies require marketing, field force and promotional spending. But expenses should translate into revenue growth.
Then examine finance cost. Companies with low debt or net cash positions are safer. A debt-free pharma company has more flexibility to invest in new products, capacity and exports.
After that, study working capital. Check inventory days, trade debts, advances from customers, cash balance and short-term borrowings. A pharma company with strong brands and advance-payment distributor terms can generate good operating cash flow.
Finally, review capex and plant investment. Capex in pharma can be positive if it supports new product lines, local manufacturing, capacity expansion, export certification or in-sourcing of high-volume products. But capex should be linked to clear demand and margin improvement.


18.Valuation: How to Value Pharmaceutical Companies
Pharmaceutical companies are usually valued using P/E, EV/EBITDA, dividend yield, discounted cash flow and sometimes sum-of-the-parts methods.
The P/E ratio is common because pharma companies usually have stable earnings. However, investors must be careful. A low P/E may mean undervaluation, but it may also mean the market does not trust the sustainability of earnings. A high P/E may reflect strong brands and growth, but it can also reflect temporarily depressed earnings.
EV/EBITDA is useful when comparing companies with different debt levels. A company with high debt may look cheap on P/E during a good year but may carry higher risk.
Dividend yield matters for mature pharma companies with strong cash flows. Some listed pharma companies distribute significant dividends when profits improve.
Discounted cash flow is useful for companies with strong long-term growth, export plans, new product launches and capacity expansion.
The most important valuation question is: what multiple should a company deserve? A company with high non-essential exposure, strong brands, chronic portfolio, low debt, export potential and stable margins should deserve a higher multiple than a company with weak brands, high debt, regulated products and volatile margins.

19.Why the Sector May Not Immediately Return to Historical P/E Levels
Many investors ask why the pharmaceutical sector is not trading at its historical P/E multiples despite record profits.
The main reason is that the market is still testing the sustainability of earnings. Recent profits improved because of deregulation, price increases, lower API costs and lower finance costs. Investors want to know whether this is a permanent earnings reset or a one-time margin spike.
The second reason is regulatory risk. Medicine pricing is politically sensitive. Even if non-essential drugs are deregulated today, investors fear future intervention if prices rise too aggressively.
The third reason is that earnings growth has been partly price-led rather than purely volume-led. A sector gets a higher P/E when growth is driven by sustainable volume expansion, exports, new products and stronger market share.
The fourth reason is that pharma still trades at a premium to the broader Pakistan market. Even if pharma looks cheap versus its own history, it may still look expensive compared with other PSX sectors.
A real re-rating would require stable policy, sustained gross margins, volume recovery, export growth and evidence that companies can grow without relying only on price increases.
 

20.Key Risks for Investors
a.Regulatory Risk
The biggest risk is government intervention in pricing. If non-essential drug deregulation is reversed or limited, sector margins could come under pressure.
b.API Cost Risk
A sudden increase in API prices can reduce gross margins, especially for companies unable to pass on costs.
c.Currency Risk
Since many inputs are imported, rupee depreciation can raise landed costs. If prices do not adjust quickly, margins suffer.
d.Product Concentration Risk
Some companies rely heavily on a few brands. If one major brand faces competition, shortage, regulatory issue or demand slowdown, earnings can be affected.

e.Quality and Compliance Risk
Any quality failure can lead to recalls, regulatory penalties and reputational damage.
f.Competition Risk
Pakistan has many local and multinational pharma companies. Generic competition can reduce pricing power, especially in commodity products.
g.Export Execution Risk
Export plans may sound attractive but can take years to materialize. Regulatory approvals, registrations and distribution networks are difficult.
h.Interest Rate Risk
Companies with high borrowings are exposed to finance costs. Falling rates help, but rising rates can again pressure profits.
i.Political and Social Risk
Medicine prices directly affect patients. Public backlash can lead to policy pressure.
21.What Investors Should Track Regularly
A serious investor in pharmaceutical companies should track the following:
1.DRAP pricing notifications and policy changes

2.Essential vs non-essential product mix

3.API price trends for major molecules

4.PKR/USD exchange rate

5.Gross margin trend

6.Sales growth split between price and volume

7.New product launches

8.Export growth and new market registrations

9.Finance cost and debt levels

10.Inventory and working-capital cycle

11.Advertising and selling expense growth

12.Capacity expansion and utilization

13.Dividend payout

14.Regulatory inspections and quality issues

15.Product concentration in top brands


22.Company Types an Investor Can Prefer
A conservative investor may prefer companies with strong brands, low debt, stable dividends, strong cash flows and diversified portfolios.
A growth investor may prefer companies launching new products, expanding exports, entering chronic therapies, nutraceuticals, biosimilars or consumer healthcare.
A value investor may look for companies trading at low P/E multiples despite improved margins and balance-sheet strength.
A turnaround investor may look for companies with depressed earnings that could recover due to lower finance costs, restructuring, product rationalization or deregulation.
But in all cases, investors should avoid buying solely because the sector is popular. Each company must be analyzed separately.
Interesting Facts for Investors
First, APIs are often bought in bulk. Bigger companies can negotiate better rates and manage inventory more efficiently.

Second, MNCs often source APIs or finished products from parent companies or approved group suppliers. This supports quality and reliability but may limit procurement flexibility.

Third, local companies can source from different suppliers globally, especially China and India. This can reduce cost but increases quality-control responsibility.

Fourth, a company can show high accounting profit but weak cash flow if inventory builds up or receivables rise. In pharma, strong brands often avoid this problem because distributor payments are advance or very quick.

Fifth, OTC products can be advertised, but prescription medicines generally cannot be marketed directly to patients through mass media.

Sixth, packaging is not a small cost. Aluminum foil, PVC/PVDC film, bottles, tubes and cartons can materially affect margins.

Seventh, a product’s regulatory classification matters more than its brand name. The addition of Caffeine along with Paracetamol (an essential molecule) can render it into non-essential category. So, one needs to find out whether composition has rendered a medicine into essential or non-essential list. Not every Panadol-branded product has the same pricing economics.

Eighth, exports can be constrained by home-country prices because some importing countries use origin-country prices or reference-pricing mechanisms.

Ninth, API localization is not simply a matter of desire. It requires scale, chemistry, environmental compliance, utilities, capital, export markets and technical expertise.

Tenth, a negative cash conversion cycle is a major hidden strength. A pharma company that receives advance payments from distributors can grow without heavy working-capital stress.


23.Conclusion: The Investor’s Core Framework
The pharmaceutical sector in Pakistan is attractive because it combines defensive demand, strong brands, improving pricing flexibility, margin recovery and long-term healthcare growth. The 2024 deregulation of non-essential drug prices changed the sector’s earnings outlook and helped companies recover from years of cost pressure.
But the sector is not risk-free. It remains highly regulated, import-dependent and politically sensitive. The best pharmaceutical companies will be those that combine strong brands, favorable product mix, pricing power, procurement efficiency, quality manufacturing, low debt, export potential and disciplined capital allocation.
Before investing in any pharmaceutical company, an investor should ask five simple questions:
1.Does the company have pricing power?

2.Is its portfolio essential, non-essential, OTC, chronic or commodity generic?

3.Can it protect margins against API, packaging and currency shocks?

4.Are earnings growing because of sustainable volume and product growth or only because of price increases?

5.Does the valuation already reflect the good news?